WallStreetZenWallStreetZen

NASDAQ: CSBR
Champions Oncology Inc Stock Forecast, Predictions & Price Target

Analyst price target for CSBR

Based on 1 analyst offering 12 month price targets for Champions Oncology Inc.
Min Forecast
$7.50+32.28%
Avg Forecast
$7.50+32.28%
Max Forecast
$7.50+32.28%

Should I buy or sell CSBR stock?

Based on 1 analyst offering ratings for Champions Oncology Inc.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CSBR stock forecasts and price targets.

CSBR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-09-22

1 of 1

Forecast return on equity

Is CSBR forecast to generate an efficient return?
Company
N/A
Industry
23.91%
Market
35.26%

Forecast return on assets

Is CSBR forecast to generate an efficient return on assets?
Company
N/A
Industry
10.31%

CSBR revenue forecast

What is CSBR's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$55.7M+11.47%
Avg 2 year Forecast
$62.6M+25.26%
CSBR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CSBR revenue growth forecast

How is CSBR forecast to perform vs Biotechnology companies and vs the US market?
Company
11.47%
Industry
1,701.16%
Market
46.14%
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CSBR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CSBR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CSBR$5.67$7.50+32.28%Strong Buy
LPTX$3.01$14.75+390.03%Strong Buy
ANEB$3.00$6.67+122.46%Strong Buy
TIL$11.75$47.00+300.00%Buy
THTX$1.70N/AN/A

Champions Oncology Stock Forecast FAQ

Is Champions Oncology Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CSBR) stock is to Strong Buy CSBR stock.

Out of 1 analyst, 1 (100%) are recommending CSBR as a Strong Buy, 0 (0%) are recommending CSBR as a Buy, 0 (0%) are recommending CSBR as a Hold, 0 (0%) are recommending CSBR as a Sell, and 0 (0%) are recommending CSBR as a Strong Sell.

If you're new to stock investing, here's how to buy Champions Oncology stock.

What is CSBR's revenue growth forecast for 2024-2025?

(NASDAQ: CSBR) Champions Oncology's forecast annual revenue growth rate of 11.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 1,701.16%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 46.14%.

Champions Oncology's revenue in 2024 is $49,978,000.On average, 1 Wall Street analysts forecast CSBR's revenue for 2024 to be $757,308,760, with the lowest CSBR revenue forecast at $757,308,760, and the highest CSBR revenue forecast at $757,308,760.

In 2025, CSBR is forecast to generate $850,969,814 in revenue, with the lowest revenue forecast at $850,969,814 and the highest revenue forecast at $850,969,814.

What is CSBR's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: CSBR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 10.31%.

What is CSBR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CSBR price target, the average CSBR price target is $7.50, with the highest CSBR stock price forecast at $7.50 and the lowest CSBR stock price forecast at $7.50.

The Wall Street analyst predicted that Champions Oncology's share price could reach $7.50 by Sep 22, 2024. The average Champions Oncology stock price prediction forecasts a potential upside of 32.28% from the current CSBR share price of $5.67.

What is CSBR's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: CSBR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.